1
|
Clinical practice guidelines for full-cycle standardized management of bone health in breast cancer patients. CANCER INNOVATION 2024; 3:e111. [PMID: 38948531 PMCID: PMC11212291 DOI: 10.1002/cai2.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/24/2023] [Revised: 01/07/2024] [Accepted: 01/09/2024] [Indexed: 07/02/2024]
Abstract
Bone health management for breast cancer spans the entire cycle of patient care, including the prevention and treatment of bone loss caused by early breast cancer treatment, the adjuvant application of bone-modifying agents to improve prognosis, and the diagnosis and treatment of advanced bone metastases. Making good bone health management means formulating appropriate treatment strategies and dealing with adverse drug reactions, and will help to improve patients' quality of life and survival rates. The Breast Cancer Expert Committee of the National Cancer Center for Quality Control organized relevant experts to conduct an in-depth discussion on the full-cycle management of breast cancer bone health based on evidence-based medicine, and put forward reasonable suggestions to guide clinicians to better deal with health issues in bone health clinics.
Collapse
|
2
|
Brekhus C, Labus K, Seguin B, Puttlitz C, Gadomski B. Patient-specific finite element modeling for fracture risk prediction in a canine model of osteosarcoma. ANNALS OF TRANSLATIONAL MEDICINE 2024; 12:5. [PMID: 38304903 PMCID: PMC10777249 DOI: 10.21037/atm-23-1699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Accepted: 10/11/2023] [Indexed: 02/03/2024]
Abstract
Background In cancer patients with bone tumors, pathological fractures are a major concern. Making treatment decision for these patients requires an evaluation of fracture risk, which is currently based on semi-qualitative criteria that lack patient-specificity. Because of this, there exists a need for quantitative fracture risk prediction tailored to the patient's individual bone geometry. To address this need, this study aims to develop and validate a finite element (FE) technique that can be used to create patient-specific models and more accurately identify fracture risk. Model validation was performed using canine radii. Methods Radii were harvested from eight canines euthanized for reasons unrelated to the study. A semicircular osteotomy was made in the distal portion of each bone to simulate tumor lysis. Samples underwent computed tomography (CT) scanning and were randomly assigned to loading groups for destructive mechanical testing. Three samples were tested in torsion, three in cantilever bending, and two in compression. FE models were created for each bone from the corresponding CT scan to replicate patient-specific geometry. Material properties were based on equations relating scan properties to elastic modulus. Boundary conditions and loads were added to the models based on the sample's treatment group. Stiffness and strain data were collected from both the mechanical testing and FE simulation, and yield load predictions were made based on maximum principal strain. Experimental and computational results were compared using a linear regression. Results The FE models were most accurate in predicting stiffness, followed by strain, with yield load having the lowest accuracy. Linear regressions resulted in R2 values of 0.9335 for bending and compression and 0.8798 for torsion. Conclusions The proposed FE technique is a valid method for predicting fracture in a canine model of osteosarcoma. This method could provide patient-specific, quantitative data to aid clinicians in decisions regarding surgical intervention for patients with bone tumors.
Collapse
Affiliation(s)
- Chloe Brekhus
- Orthopaedic Bioengineering Research Laboratory, Department of Mechanical Engineering, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA
| | - Kevin Labus
- Orthopaedic Bioengineering Research Laboratory, Department of Mechanical Engineering, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA
| | - Bernard Seguin
- VCA Central Victoria Veterinary Hospital, Victoria, BC, Canada
| | - Christian Puttlitz
- Orthopaedic Bioengineering Research Laboratory, Department of Mechanical Engineering, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA
| | - Benjamin Gadomski
- Orthopaedic Bioengineering Research Laboratory, Department of Mechanical Engineering, C. Wayne McIlwraith Translational Medicine Institute, Colorado State University, Fort Collins, CO, USA
| |
Collapse
|
3
|
Bocchi MB, Meschini C, Pietramala S, Perna A, Oliva MS, Matrangolo MR, Ziranu A, Maccauro G, Vitiello R. Electrochemotherapy in the Treatment of Bone Metastases: A Systematic Review. J Clin Med 2023; 12:6150. [PMID: 37834793 PMCID: PMC10573742 DOI: 10.3390/jcm12196150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2023] [Revised: 09/08/2023] [Accepted: 09/20/2023] [Indexed: 10/15/2023] Open
Abstract
BACKGROUND AND AIM Cancers are one of the most frequent causes of death and disability in humans. Skeletal involvement has a major impact on the quality of life and prognosis of cancer patients. Electrochemotherapy is a palliative and minimally invasive oncologic treatment that was first used to treat subcutaneous nodules for malignant tumors. The aim of our review is to evaluate the results of electrochemotherapy in the treatment of bone metastases. METHODS A systematic review of the literature indexed in the PubMed MEDLINE and Cochrane Library databases using the search key words "electrochemotherapy" AND ("metastasis" OR "metastases") was performed. The Preferred Reporting Items for Systematic Reviews and MetaAnalyses was followed. Inclusion criteria were proven involvement of the appendicular skeleton in metastatic carcinoma or melanoma, through at least one percutaneous electrochemotherapy session on the metastatic bone lesion. The exclusion criterion was no skeletal metastatic involvement. RESULTS Eight articles were finally included. We reached a population of 246 patients. The mean age and follow up were 60.1 years old and 11.4 months, respectively. The most represented primary tumor was breast cancer (18.9%). A total of 250 bone lesions were treated with electrochemotherapy. According to RECIST criteria, in our population we observed 55.5% stable diseases. The mean pre-electrochemotherapy VAS value was 6.9, which lowered to 2.7 after treatment. Adverse events occurred in 3.4% of patients. CONCLUSIONS Electrochemotherapy as a minimally invasive and tissue-sparing treatment should be considered for patients with no other alternative to obtain tumor control and improvement in quality of life.
Collapse
Affiliation(s)
- Maria Beatrice Bocchi
- Department of Orthopaedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
- Department of Orthopaedics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Cesare Meschini
- Department of Orthopaedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
- Department of Orthopaedics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Silvia Pietramala
- Department of Orthopaedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
- Department of Orthopaedics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Andrea Perna
- Department of Orthopaedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
- Department of Orthopaedics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Maria Serena Oliva
- Departement of Orthopaedics, Ospedale San Giovanni Evangelista, 00019 Tivoli, Italy
| | - Maria Rosaria Matrangolo
- Department of Orthopaedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
- Department of Orthopaedics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Antonio Ziranu
- Department of Orthopaedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
- Department of Orthopaedics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Giulio Maccauro
- Department of Orthopaedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
- Department of Orthopaedics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| | - Raffaele Vitiello
- Department of Orthopaedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
- Department of Orthopaedics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
| |
Collapse
|
4
|
Gorbacheva L, Potapov M, Taran V. Decompression Surgery Options for Metastatic Cervical Spine Lesions. J Cancer 2023; 14:843-849. [PMID: 37056392 PMCID: PMC10088883 DOI: 10.7150/jca.81594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Accepted: 02/10/2023] [Indexed: 04/15/2023] Open
Abstract
Background: Metastatic spinal lesions occur in 70% of patients with incurable cancer, and the most common site for bone metastases is the spine. Over the last decade, medical science has made significant progress in treating tumor damage to the spine. The study examined the efficacy of decompression surgery for patients with metastatic cervical spine lesions contributing to spinal cord compression. Methods: The study enrolled 38 patients (27 females and 11 males, average age of 61.35±8.49 years) with metastatic cervical spine lesions resulting in cord compression relieved with surgery. Patients experienced improvement in pain and motor within one month of surgery addressing cervical metastatic disease. Results: Complete or partial regression of pain syndrome 10 days after surgery was observed in 26 (68.4%) patients, one month later - in 33 (86.8%) patients, one year later - in 35 (92.1%) patients. Regression of neurological symptoms on the 10th day after surgery was observed in 8 (21.1%) patients, one month later - in 21 (55.3%) patients, one year later - in 34 (89.5%) patients. Two patients died between 3 and 12 months after surgery, having a worsening of their neurological status and pain syndrome. Conclusions: Decompression surgeries for metastatic lesions of the cervical spine with spinal cord compression resulted in effective reduction of pain and neurological dysfunction.
Collapse
Affiliation(s)
- Liubov Gorbacheva
- Kuban State Medical University, Krasnodar, Russian Federation
- ✉ Corresponding author:
| | - Mikhail Potapov
- Kemerovo State Medical University, Kemerovo, Russian Federation
| | - Vadim Taran
- Kemerovo State Medical University, Kemerovo, Russian Federation
| |
Collapse
|
5
|
Trends in Diagnosis and Surgical Treatment of Bone Metastases among Orthopedic Surgeons. J Clin Med 2022; 11:jcm11154284. [PMID: 35893375 PMCID: PMC9341391 DOI: 10.3390/jcm11154284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Revised: 06/27/2022] [Accepted: 07/22/2022] [Indexed: 12/10/2022] Open
Abstract
Background: The proper diagnosis and treatment of bone metastases are essential for patient survival. However, several strategies for the treatment are practiced. Therefore, the aim of the study was to analyze what factors influence the choice of a method of treatment. Methods: An online survey was conducted within the Polish Society of Orthopedics and Traumatology. It consisted of 45 questions and was divided into four main parts: Participant Characteristics, Diagnosis and Qualification, Treatment, and Clinical Cases. Results: A total number of 104 responses were collected. The most frequently chosen methods were: Intramedullary nail (IMN) + Resection + Polymethyl methacrylate (PMMA) (30.47%) and IMN without tumor resection (42.13%), and in third place, modular endoprosthesis (17.25%). The less experienced group of orthopedic surgeons more often (47.5% vs. 39.5%) decided to perform IMN without tumor resection than the more experienced group (p = 0.046). Surgeons from district hospitals less frequently (13.7% vs. 23.1%) would decide to use modular endoprosthesis than surgeons from university hospitals (p = 0.000076). Orthopedists who performed ≥ 11 bone metastases surgeries per year would more often use modular endoprosthesis (34.8% vs. 13.2%) than those who performed ≤ 10 operations per year (p = 0.000114). Conclusion: Experience, place of work, and the number of metastasis surgeries performed during a year may influence the choice of treatment method in patients with bone metastases.
Collapse
|
6
|
Monitoring and personalization in treatment of breast cancer patients with metastatic bone lesions. EUREKA: HEALTH SCIENCES 2022. [DOI: 10.21303/2504-5679.2022.002270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The aim. To increase the efficiency of treatment of BC patients with metastatic lesions of long tubular bones by using, Multidetector computed tomography (MDCT) and bone marrow markers for diagnostics and monitoring the clinical course of the oncologic process, accompanied by surgical intervention with endoprosthetics along with the treatment of polymorbid pathology in a specific patient.
Materials and methods. Authors provide systemic personification including visualization of the tumor site and its vascularization; printing out the 3D model; surgical planning, including optimal surgical access to the tumor site considering the volume and topographic and anatomical location and dissemination of the tumor, the convenience of intraoperative tasks (removal of the tumor, bone grafting or endoprosthetics), preoperative planning of bone resection lines with maximum preservation of intact bone tissue.
Results. Personalization of the treatment of breast cancer patients with metastatic bone lesions contributes to a significant reduction in postoperative complications of endoprosthetic replacement of large joints (up to 15.2 %) and increases the overall three-year survival rate (up to 40.6 %), as well as significantly improves their quality of life.
Conclusions. The personalization of treatment of patients with tumor lesions of the skeletons contributes to a significant decrease in the indicator of postoperative complications of endoprosthetics of great joints and to an increase in the total three-year survival rate, as well as to the improvement of the quality of life after the conducted treatment.
Collapse
|
7
|
Reipond L, Ford D, Cool P. A Rare Presentation of a Solitary Melanoma Bone Metastasis. Cureus 2022; 14:e21479. [PMID: 35223259 PMCID: PMC8860680 DOI: 10.7759/cureus.21479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/21/2022] [Indexed: 11/05/2022] Open
Abstract
A 74-year-old woman presented with sudden onset pain and swelling in her right wrist. Plain radiographs showed a pathological fracture through a lytic lesion. The patient had a past medical history of melanoma on her right thigh, which had been excised two years previously. She was referred to the bone cancer unit to undergo a series of investigations that included a magnetic resonance imaging scan, bone scintigraphy and a computed tomography-guided biopsy. Collectively, all investigations revealed a solitary bone metastasis from her previous melanoma in the right distal radius. The patient was treated symptomatically and underwent internal fixation with cement augmentation for symptom control. With the incidence of melanoma increasing, this case demonstrates the importance of being vigilant of unusual presentations.
Collapse
|
8
|
Bukharov AV, Derzhavin VA, Yadrina AV, Erin DA, Elkhov DO, Aliev MD. [Surgical treatment of patients with chest wall metastases]. Khirurgiia (Mosk) 2022:25-30. [PMID: 35920219 DOI: 10.17116/hirurgia202208125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
OBJECTIVE To evaluate postoperative outcomes in patients with chest wall metastases. MATERIAL AND METHODS We analyzed 40 patients who underwent surgery for chest wall metastatic lesions. Fourteen (35%) patients had sternal lesion, 26 (65%) ones - rib metastases. We used implants for chest wall defect closure in 15 (37.5%) patients. Chest wall repair with autologous tissues was performed in 19 (47.5%) patients. RESULTS Median survival was 17 months. Most patients (n=30, 75%) showed improvement in the quality of life according to Karnofsky and EGOG scale after surgery. Continued tumor growth occurred in 4 (10%) patients within 8-16 months after surgery. There were 2 patients who suffered from tumor recurrence accompanied by other metastatic foci (progression). Complications were diagnosed in 5 (12.5%) patients. Tactical errors were identified in 4 (10%) patients and they were associated with progression of cancer in the form of new metastatic foci within 6 months after surgery. CONCLUSION Active surgical approach for bone metastases in patients with favorable cancer-related prognosis can improve quality of life and survival at least in case of solitary lesions. New program for treatment strategy selection based on prognosis of life expectancy and algorithms of surgical treatment will reduce the risk of erroneous management and increase its effectiveness.
Collapse
Affiliation(s)
- A V Bukharov
- Hertsen Moscow Cancer Research Institute, Moscow, Russia
| | - V A Derzhavin
- Hertsen Moscow Cancer Research Institute, Moscow, Russia
| | - A V Yadrina
- Hertsen Moscow Cancer Research Institute, Moscow, Russia
| | - D A Erin
- Hertsen Moscow Cancer Research Institute, Moscow, Russia
| | - D O Elkhov
- Hertsen Moscow Cancer Research Institute, Moscow, Russia
| | - M D Aliev
- Hertsen Moscow Cancer Research Institute, Moscow, Russia
| |
Collapse
|
9
|
Brozovich A, Garmezy B, Pan T, Wang L, Farach-Carson MC, Satcher RL. All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma. J Bone Oncol 2021; 31:100399. [PMID: 34745857 PMCID: PMC8551072 DOI: 10.1016/j.jbo.2021.100399] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 10/18/2021] [Accepted: 10/19/2021] [Indexed: 01/05/2023] Open
Abstract
Renal cell carcinoma (RCC) is the most common malignancy of the kidney, representing 80-90% of renal neoplasms, and is associated with a five-year overall survival rate of approximately 74%. The second most common site of metastasis is bone. As patients are living longer due to new RCC targeting agents and immunotherapy, RCC bone metastases (RCCBM) treatment failure is more prevalent. Bone metastasis formation in RCC is indicative of a more aggressive disease and worse prognosis. Osteolysis is a prominent feature and causes SRE, including pathologic fractures. Bone metastasis from other tumors such as lung, breast, and prostate cancer, are more effectively treated with bisphosphonates and denosumab, thereby decreasing the need for palliative surgical intervention. Resistance to these antiresportives in RCCBM reflects unique cellular and molecular mechanisms in the bone microenvironment that promote progression via inhibition of the anabolic reparative response. Identification of critical mechanisms underlying RCCBM induced anabolic impairment could provide needed insight into how to improve treatment outcomes for patients with RCCBM, with the goals of minimizing progression that necessitates palliative surgery and improving survival.
Collapse
Affiliation(s)
- Ava Brozovich
- Texas A&M College of Medicine, Bryan, TX, USA
- Department of Regenerative Medicine, Houston Methodist Research Institute, Houston, TX, USA
- Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, TX, USA
| | - Benjamin Garmezy
- Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Tianhong Pan
- Department of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Liyun Wang
- Department of Mechanical Engineering, Center for Biomedical Engineering Research, University of Delaware, Newark, DE, USA
| | - Mary C. Farach-Carson
- Department of Diagnostic and Biomedical Sciences, UT Health Science Center School of Dentistry, Houston, TX, USA
| | - Robert L. Satcher
- Department of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|